Outcomes of peripheral blood stem cell transplantation patients from HLA-mismatched unrelated donor with antithymocyte globulin (ATG)-Thymoglobulin versus ATG-Fresenius: a single-center study

详细信息    查看全文

• 作者：Wenrong Huang ; Xiaoli Zhao ; Yamin Tian ; Tingting Cao ; Yanfen Li…
• 关键词：Unrelated donor ; Peripheral blood stem cell transplantation ; HLA ; mismatched ; ATG ; Thymoglobulin ; ATG ; Fresenius
• 刊名：Medical Oncology
• 出版年：2015
• 出版时间：February 2015
• 年：2015
• 卷：32
• 期：2
• 全文大小：264 KB
• 参考文献：1. Valcárcel D, Sierra J, Wang T, Kan F, Gupta V, Hale GA, et al. One-antigen mismatched related versus HLA-matched unrelated donor hematopoietic stem cell transplantation in adults with acute leukemia: Center for International Blood and Marrow Transplant Research results in the era of molecular HLA typing. Biol Blood Marrow Transplant. 2011;17(5):640-. CrossRef
  2. Cheuk DK. Optimal stem cell source for allogeneic stem cell transplantation for hematological malignancies. World J Transplant. 2013;3(4):99-12.
  3. Anasetti C, Logan BR, Lee SJ, et al. Peripheral-blood stem cells versus bone marrow from unrelated donors. N Engl J Med. 2012;367(16):1487-6. CrossRef
  4. Bacigalupo A. Matched and mismatched unrelated donor transplantation: is the outcome the same as for matched sibling donor transplantation? Hematology Am Soc Hematol Educ Program. 2012;2012:223-. doi:10.1182/asheducation-2012.1.223 .
  5. Pidala J, Tomblyn M, Nishihori T, et al. ATG prevents severe acute graft-versus-host disease in mismatched unrelated donor hematopoietic cell transplantation. Biol Blood Marrow Transplant. 2011;17(8):1237-4. CrossRef
  6. Sheng Z, Ma H, Pang W, Niu S, Xu J. In vivo T-cell depletion with antithymocyte globulins improves overall survival after myeloablative allogeneic stem cell transplantation in patients with hematologic disorders. Acta Haematol. 2013;129(3):146-3. CrossRef
  7. Gaber AO, Monaco AP, Russell JA, Lebranchu Y, Mohty M. Rabbit antithymocyte globulin (thymoglobulin): 25?years and new frontiers in solid organ transplantation and haematology. Drugs. 2010;70(6):691-32. CrossRef
  8. Mueller TF. Thymoglobulin: an immunologic overview. Curr Opin Organ Transplant. 2003;8:305-2. CrossRef
  9. Kumar A, Mhaskar AR, Reljic T, et al. Antithymocyte globulin for acute-graft-versus-host-disease prophylaxis in patients undergoing allogeneic hematopoietic cell transplantation: a systematic review. Leukemia. 2012;26(4):582-. CrossRef
  10. Penack O, Fischer L, Gentilini C, et al. The type of ATG matters: natural killer cells are influenced differentially by Thymoglobulin Lymphoglobulin and ATG-Fresenius. Transpl Immunol. 2007;18(2):85-. CrossRef
  11. Ayuk F, Diyachenko G, Zabelina T, et al. Anti-thymocyte globulin overcomes the negative impact of HLA mismatching in transplantation from unrelated donors. Exp Hematol. 2008;36(8):1047-4. CrossRef
  12. Huang WR, Li HH, Gao CJ, et al. Unmanipulated HLA-mismatched/haploidentical peripheral blood stem cell transplantation for high-risk hematologic malignancies. Transfusion. 2012;52(6):1354-2. CrossRef
  13. Sullivan KM. Graft-versus-host disease. In: Blume KG, Forman SJ, Appelbaum FR, editors. Thomas-hematopoietic Cell transplantation. 3rd ed. Malden: Blackwell Publishing Ltd; 2004. p. 633-4.
  14. Shin SH, Yoon JH, Yahng SA, et al. PBSC vs BM grafts with myeloablative conditioning for unrelated donor transplantation in adults with high-risk ALL. Bone Marrow Transplant. 2014;49(6):773-. CrossRef
  15. Pidala J. Graft-vs-host disease following allogeneic hematopoietic cell transplantation. Cancer Control. 2011;18(4):268-6.
  16. Remberger M, Svahn BM, Hentschke P, Lofgren C, Ringden O. Effect on cytokine release and graft-versus-host disease of different anti-T cell antibodies during conditioning for unrelated haematopoietic stem cell transplantation. Bone Marrow Transplant. 1999;24(8):823-0. CrossRef
  17. Basara N, Baurmann H, Kolbe
• 刊物主题：Oncology; Hematology; Pathology; Internal Medicine;
• 出版者：Springer US
• ISSN：1559-131X

文摘

Although antithymocyte globulin (ATG) had been widely used in hematopoietic stem cell transplantation from unrelated donor due to its ability to prevent acute and chronic graft-versus-host disease (GVHD), the comparative efficacy and safety of ATG-Thymoglobulin (ATG-T) and ATG-Fresenius (ATG-F) in patients undergoing HLA-mismatched allogeneic peripheral blood stem cell transplantation from unrelated donors (UR-PBSCT) has not been evaluated. Retrospective analysis of patients who underwent HLA-mismatched UR-PBSCT between January 2003 and December 2013 and received pre-transplant ATG-T at a total dose of 10?mg/kg or ATG-F at a total dose of 20?mg/kg was performed. Patients who received ATG-T (n?=?23) or ATG-F (n?=?28) had similar baseline demographic, disease, and transplant characteristics. There were no significant between-groups differences in the probability of acute GVHD (P?=?0.721) and chronic GVHD (P?=?0.439). ATG-F was associated with nonsignificant trends toward higher disease-free survival at 3-year follow-up compared with ATG-T (45.7?±?11.1 vs 61.3?±?9.7?%, respectively, P?=?0.07). A significantly greater proportion of ATG-T patients experienced high fever than ATG-F patients (P?